New Year Investment Club 2021

Douglas Eby is the inaugural Senior Fellow for the Innovative Funding Models Project at Harvard. Doug’s role is to advance the work of the Project by developing a policy/research agenda, planning the convening of the working group, co-authoring a report on the working group's findings, and being available as a resource for interested members of the Harvard community. As a 2017 Fellow in Harvard University’s Advanced Leadership Initiative, Doug’s efforts have been focused on innovative financing models to meet the unprecedented gap that currently exists in translational research. His work at Harvard led to the formation of Cambridge Science Corporation, where Doug serves as the Chief Executive Officer. Cambridge Science Corporation’s mission is to improve global health by accelerating the pace of medical technology innovation. Prior to founding Cambridge Science, Doug worked in the investment management industry. He has extensive experience in the health care sector as an institutional investor across all stages of the capital continuum: public, private equity, venture capital, and angel startup financings. Most recently, Doug was the President and Portfolio Manager for an investment advisor managing institutional assets for clients in the US equity markets deploying a long-term value-based strategy. Doug has served as a director of several NYSE listed public companies including the Markel Corporation, Level 3 Communications, and CBRE Realty Finance, and as an advisory director of the Student Loan Marketing Association (Sallie Mae). He has served on the boards of numerous nonprofits including Suburban Hospital-Johns Hopkins Medicine, where he was chairman of the hospital's investment committee, and the Boys and Girls Clubs of Greater Washington, DC, where he served as chairman of the board.

Baillie Gifford’s sole business is investment management. Since the company was founded in 1908 it has been a partnership. Today it is owned by 46 partners all of whom work in the business. We believe that the best investment ideas spring from thinking about future possibilities, not short-term probabilities. We set no barriers to the imagination of our investors, encouraging fresh perspectives and the use of diverse sources of information. We term ourselves Actual Investors. We currently manage or advise some £197bn on behalf of clients worldwide. Whilst we are predominantly an institutional manager (circa 85% of FUM), we offer an extensive range of investment trusts and open ended funds to UK wealth managers and intermediaries.

CMT’s patented biosensor is a painless non-invasive device that within seconds collects nanolitres of fluid from the skin and instantly analyses it quantitatively for levels of blood biomarkers, such as glucose, lactate, alcohol, troponin, cortisol, etc. Blood biomarkers are critical indicators of health but blood tests are not real time and do not provide a trend. CMT’s devices provide real-time patient information between blood tests, allowing early detection of disease and, over time, personalised health care. CMT is currently concluding five independent clinical trials at three Harvard hospitals and at the world-leading Mayo Clinic ahead of FDA approval later this year. CMT qualifies as a Knowledge-Intensive EIS company.

Natixis Investment Managers serves financial professionals with more insightful ways to construct portfolios. Powered by the expertise of 26 specialized investment managers globally, we apply Active Thinking℠ to deliver proactive solutions that help clients pursue better outcomes in all markets. Natixis ranks among the world’s largest asset management firms1 ($1,067.3 billion AUM2). Natixis Investment Managers includes all of the investment management and distribution entities affiliated with Natixis Distribution, L.P. and Natixis Investment Managers S.A. Services/products are not available to all investors in all jurisdictions. 1 Cerulli Quantitative Update: Global Markets 2017 ranked Natixis Investment Managers (formerly Natixis Global Asset Management) as the 15th largest asset manager in the world based on assets under management as of December 31, 2016. 2 Net asset value as of September 30, 2020.